Healthcare

Healthcare, the world's largest industry, is transforming faster than ever. The focus on outcomes based medicine and optimal health management of populations will result in major seismic shifts. Modernization and reform measures are being employed globally by public and private sector organizations to meet the growing need for healthcare. New technologies are being created, offering enormous promise to improve care delivery.

Our Transformational Health practice serves all key industry stakeholders through partnership models that provide access to high-quality content and our global team of industry experts. The practice includes Visionary Health, Life Sciences, Advanced Medical Technologies and Connected Health, focusing on evolving healthcare technologies and covering the entire industry spectrum

  1. 08 Jun 2018  |  North America

    US Cardiac Troponin Diagnostics Market, Forecast to 2021

    High Prevalence of Heart Disease Propels Market Growth

    Cardiac troponins help to diagnose nearly two-thirds of the patients in the diagnosis Acute Coronary Syndrome (ACS) who are missed out by Echocardiogram (ECG). ECG can detect only one-third of the patients with persistent ST-segment Elevation (STEMI), whereas cardiac troponins can distinguish patients without ST-segment elevation (NSTEACS; non-ST s...

    $4,950.00
  2. 25 May 2018  |  Europe

    Western European Cardiac Troponin Diagnostics Market, Forecast to 2021

    Emerging Biomarkers Disrupt and Spur Growth in the Heart Disease Segment

    Cardiac troponins have now become the gold standard for early diagnosis of acute myocardial infarction, making them indispensable for clinical diagnosis of Acute Coronary Syndrome (ACS). Cardiac troponins play a key role in minimizing hospital stays and reducing admission rate which are the biggest contributors to overall healthcare expenditure. Fo...

    $3,000.00
  3. 16 Apr 2018  |  Asia Pacific

    Analysis of the APAC Cardiac Troponin Diagnostics Market, Forecast to 2021

    Increasing Incidence Rates of Myocardial Infarction and Aging Population in APAC Drive the Troponin Diagnostics Market

    Cardiac troponins will continue to remain the gold standard for early diagnosis of acute myocardial infarction (AMI); however, the key challenge to address is the advent of a complementary biomarker to prevent repeat diagnosis. Multiplexing platforms should be harnessed for simultaneous testing of complementary biomarkers such as H-FABP, cardiac my...

    $3,000.00